Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.

Bayer

Sorafenib